SGLT-2 inhibitors now support heart and kidney care, driving the market to $32.16B by 2033 expanding beyond diabetes management.
Rising global burden of cardiometabolic diseases fuels SGLT-2 inhibitors market growth, projected to reach $32.16B by 2033.